DDInter221 DDInter1676
Boceprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as Boceprevir. Boceprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotypes 1 and 4 [synthesis]. These enzymes are essential for viral replication and serve to cleave the virally encoded polyprotein into mature proteins like NS4A, NS4B, NS5A and NS5B [FDA Label]. The barrier
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Boceprevir {u} (Compound) resembles {v} (Compound) Telaprevir
Boceprevir {u} (Compound) binds {v} (Gene) CMA1
Boceprevir {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Boceprevir {u} (Compound) causes {v} (Side Effect) Sepsis
Boceprevir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nintedanib
Boceprevir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabazitaxel
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Glasdegib
Boceprevir {u} may lead to a major life threatening interaction when taken with {v} Apixaban
Boceprevir (Compound) resembles Telaprevir (Compound)
Boceprevir (Compound) binds CMA1 (Gene)
Boceprevir (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class)
Boceprevir (Compound) causes Sepsis (Side Effect)
Boceprevir may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Boceprevir may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Boceprevir may lead to a major life threatening interaction when taken with Glasdegib
Boceprevir may lead to a major life threatening interaction when taken with Apixaban